TARSHealthcareMid-Cap
Tarsus Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Tarsus Pharmaceuticals, Inc. (TARS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are TARS insiders buying or selling?
Tarsus Pharmaceuticals, Inc. insiders reported 8 open-market buys ($16.5M) and 136 sells ($60.2M) across 144 Form 4 filings — a net selling position of $43.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 22, 2026)
Total Form 4 filings
144
SEC EDGAR
Insider filers
19
Insider buys (8)
$16.5M
Insider sells (136)
$60.2M
Insider sentiment
Net sellingNet insider flow of $43.7M in net selling.
Recent TARS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 10.0K | $61.55 | $615.5K |
| Jun 17, 2026 | Jeffrey S Farrow | Chief Financial Officer and Chief Strategy Officer | Sale | 14.4K | $60.95 | $877.4K |
| Jun 17, 2026 | Katherine Goodrich | Director | Sale | 3.0K | $62.08 | $183.4K |
| Jun 17, 2026 | Phd J Link William | Director | Sale | 12.5K | $62.12 | $776.5K |
| Mar 24, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 3.0K | $66.75 | $199.5K |
| Mar 19, 2026 | Dianne C. Whitfield | Chief Human Resources Officer | Sale | 12.3K | $68.36 | $839.1K |
| Mar 19, 2026 | Bryan Wahl | General Counsel | Sale | 12.4K | $68.36 | $850.4K |
| Mar 19, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 11.3K | $68.21 | $772.4K |
| Mar 19, 2026 | Aziz Mottiwala | Chief Commercial Officer | Sale | 13.1K | $68.36 | $892.5K |
| Mar 19, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 1.1K | $68.36 | $78.2K |
| Mar 19, 2026 | Jeffrey S Farrow | Chief Financial Officer and Chief Strategy Officer | Sale | 6.4K | $68.36 | $439.6K |
| Mar 19, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 34.6K | $68.34 | $2.4M |
| Mar 18, 2026 | Phd J Link William | Director | Sale | 12.5K | $68.79 | $859.8K |
| Jan 6, 2026 | Dianne C. Whitfield | Chief Human Resources Officer | Sale | 15.6K | $80.67 | $1.3M |
| Dec 30, 2025 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 6.0K | $82.51 | $495.1K |
| Dec 18, 2025 | Dianne C. Whitfield | Chief Human Resources Officer | Sale | 7.4K | $80.10 | $592.5K |
| Dec 17, 2025 | Phd J Link William | Director | Sale | 22.9K | $81.26 | $1.9M |
| Dec 17, 2025 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 2.1K | $79.50 | $165.2K |
| Sep 26, 2025 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 6.0K | $55.37 | $332.2K |
| Sep 10, 2025 | Phd J Link William | Director | Sale | 27.1K | $57.00 | $1.5M |
| Aug 13, 2025 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 6.0K | $50.00 | $300.0K |
| Jun 18, 2025 | Jeffrey S Farrow | Chief Financial Officer and Chief Strategy Officer | Sale | 13.6K | $40.42 | $550.0K |
| Jun 17, 2025 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 1.0K | $41.08 | $41.3K |
| Jun 11, 2025 | Aziz Mottiwala | Chief Commercial Officer | Sale | 17.5K | $43.76 | $765.8K |
| Mar 26, 2025 | Bobak R. Azamian | President/CEO and Board Chair | Sale | 6.0K | $50.00 | $300.0K |
Showing the 25 most recent of 144 Form 4 filings for Tarsus Pharmaceuticals, Inc..
Most active TARS insiders
- Bobak R. Azamian51 filings
- Aziz Mottiwala14 filings
- Dianne C. Whitfield11 filings
- Leonard M. Greenstein11 filings
- Bryan Wahl9 filings
Ask anything about TARS insider activity
Use Trabud's AI agent to query Tarsus Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me TARS CEO purchases this year" or compare it against any other ticker.
Open the AI agentTARS insider trading FAQ
Are Tarsus Pharmaceuticals, Inc. insiders buying or selling?
Across 144 SEC Form 4 filings, Tarsus Pharmaceuticals, Inc. (TARS) insiders reported 8 open-market purchases totaling $16.5M and 136 sales totaling $60.2M. That is a net selling position of $43.7M.
How many insiders trade TARS stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Tarsus Pharmaceuticals, Inc.. The most recent filing was accepted on Jun 22, 2026.
Where does Trabud get TARS insider trading data?
All TARS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.